Detalhe da pesquisa
1.
Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial.
Hepatology
; 77(6): 2093-2103, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36800850
2.
Pathway to global elimination of hepatitis B: HBV cure is just the first step.
Hepatology
; 78(3): 976-990, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37125643
3.
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection.
J Hepatol
; 79(5): 1139-1149, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37524230
4.
Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.
J Hepatol
; 78(3): 513-523, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38133554
5.
Long-term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
Am J Gastroenterol
; 2023 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37561058
6.
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 study.
J Viral Hepat
; 30(3): 209-222, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36302125
7.
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Ann Intern Med
; 175(9): 1221-1229, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35939812
8.
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(8): 995-1008, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35798016
9.
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB.
J Hepatol
; 77(5): 1287-1298, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35870702
10.
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.
J Hepatol
; 77(3): 642-652, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35460726
11.
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
J Hepatol
; 77(5): 1265-1275, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35697332
12.
Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.
Hepatology
; 74(4): 1737-1749, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33704806
13.
Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B.
Hepatology
; 74(4): 1795-1808, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34037271
14.
Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
Liver Int
; 42(6): 1278-1286, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220658
15.
Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.
Clin Microbiol Rev
; 33(2)2020 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32102898
16.
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
N Engl J Med
; 378(4): 354-369, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29365309
17.
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
N Engl J Med
; 379(1): 22-31, 2018 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29972757
18.
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
J Viral Hepat
; 28(11): 1635-1642, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34448313
19.
Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection.
Hepatology
; 72(1): 7-18, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31652357
20.
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Hepatology
; 72(1): 58-71, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32115759